Therefore, constraining the TLR-4/NF-κB pathway and NLRP3 inflammasome activation would be valuable therapeutic targets for controlling pyroptosis and consequently advancing neurodegeneration in PD [151]. This evidence concerns the gene TLR4 and Parkinson disease.